TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28090335
Drug: Step-up treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up treatment with standard induction treatment (oral prednisolone or exclusive enteral nutrition) combined with azathioprine (AZA) as maintenance treatment.
Study: 28094171
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Treatment (CRT) for 12 weeks
Study: 28094314
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous (IV) esomeprazole for 72 hours
Study: 28096259
Drug: Mixed meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meal and infusion of exogenous glucose-dependent insulinotropic polypeptide (GIP)
Study: 28097013
Drug: Polyglucosamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyglucosamine (2 tablets x 2)
Study: 28097013
Drug: Orlistat (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (1 capsule x 3)
Study: 28100523
Drug: Postoperative L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative L-arginine measurement
Study: 28100523
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between logAUC(l-arginine/ADMA) and logAUC(RHI)
Study: 28100523
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between logAUC(L-arginine/ADMA) and logAUC(BH4)
Study: 28100530
Drug: Dexmedetomidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (2 mcg/kg bolus for 10 minutes)
Study: 28100627
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor receptor 1
Study: 28101105
Drug: Oral Administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Administration of nan
Study: 28101354
Drug: gemcitabine/cisplatin/S-1 (GCS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine/cisplatin/S-1 (GCS) combination therapy intravenously at doses of 1,000 mg/m² or 25 mg/m²
Study: 28103201
Drug: Anti-TNF alpha
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF alpha therapy (Adalimumab, Infliximab, Etanercept)
Study: 28103201
Drug: Anti-TNF alpha
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF alpha therapy (Adalimumab, Infliximab)
Study: 28103201
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-TNF alpha therapy)
Study: 28103831
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment for nAMD
Study: 28103831
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment for DME
Study: 28103853
Drug: Aquatic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic Therapy
Study: 28103853
Drug: Land-based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based Therapy
Study: 28104208
Drug: Polymer-free drug-filled
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer-free drug-filled stent (DFS)
Study: 28106016
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy in low-risk patients
Study: 28106016
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy in high-risk patients
Study: 28106655
Drug: Transurethral polyacrylamide
Normalized name: polyacrylamide (10000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral polyacrylamide hydrogel injection
Study: 28108386
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy and Amitriptyline (CBT+A)
Study: 28109243
Drug: Neonatal hyperbilirubinemia
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal hyperbilirubinemia treatment
Study: 28109259
Drug: Blood-pressure lowering
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-pressure lowering agents and statins
Study: 28109895
Drug: Transabdominal ultrasound-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transabdominal ultrasound-guided HIFU treatment using volumetric shell ablation technique
Study: 28109895
Drug: Transabdominal ultrasound-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transabdominal ultrasound-guided HIFU treatment
Study: 28111925
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bevacizumab, irinotecan, and temozolomide (BIT)
Study: 28114316
Drug: Women gaining
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women gaining below the Institute of Medicine guidelines
Study: 28114604
Drug: Imiquimod cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod cream, 5% applied topically once per day for 4 consecutive days on specified cycles for 12 weeks, combined with albumin bound paclitaxel, 100 mg/m2 intravenously on days 1, 8, and 15, repeated every 28 days for 12 weeks
Study: 28114884
Drug: Maternal vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal vascular endothelial growth factor (VEGF) gene therapy
Study: 28114898
Drug: Initial empirical
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial empirical antifungal therapy
Study: 28114898
Drug: Initial pre-emptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial pre-emptive antifungal therapy
Study: 28114898
Drug: Initial targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial targeted antifungal therapy
Study: 28114962
Drug: COPE intervention
Normalized name: Copernicia prunifera whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE intervention (Caregivers of cancer Outpatients' Psycho-Education support group therapy), comprising four weekly sessions targeting psychoeducation, skills training, and supportive therapy.
Study: 28116595
Drug: Early fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early fluid administration (total fluid infused in the first 6 hours)
Study: 28117498
Drug: Insomnia (measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insomnia (measured using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version)
Study: 28117498
Drug: Anxiety, type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiety, type of treatment, back muscle strength, pain severity, and stage of treatment
Study: 28117906
Drug: Integrative Cognitive-Affective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Cognitive-Affective Therapy (ICAT-BN)
Study: 28117906
Drug: Cognitive-Behavioral Therapy-Enhanced
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy-Enhanced (CBT-E)
Study: 28119295
Drug: Margetuximab (0.1-6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margetuximab (0.1-6.0 mg/kg for Regimen A, 10-18 mg/kg for Regimen B) administered by intravenous infusion, 3 of every 4 weeks for Regimen A or once every 3 weeks for Regimen B.
Study: 28119763
Drug: Vonoprazan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan (10 mg and 20 mg combined)
Study: 28119821
Drug: Laronidase treatment
Normalized name: Laronidase
DrugBank: Laronidase (DB00090)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Laronidase treatment after immunosuppression regimen with cyclosporine and azathioprine
Study: 28119821
Drug: Laronidase treatment
Normalized name: Laronidase
DrugBank: Laronidase (DB00090)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Laronidase treatment
Study: 28119821
Drug: Cyclosporine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (initial dose: 15 or 20 mg/kg/day) and azathioprine (initial dose: 2.5 or 5 mg/kg/day)
Study: 28120036
Drug: Codrituzumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codrituzumab 2.5 mg/kg qw + Sorafenib 400 mg bid
Study: 28120036
Drug: Codrituzumab 5
Normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codrituzumab 5 mg/kg qw + Sorafenib 400 mg bid
Study: 28120036
Drug: Codrituzumab 10
Normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codrituzumab 10 mg/kg qw + Sorafenib 400 mg bid
Study: 28120036
Drug: Codrituzumab 1600
Normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codrituzumab 1600 mg q2w + Sorafenib 400 mg bid
Study: 28120036
Drug: Codrituzumab 1600
Normalized name: Codrituzumab
DrugBank: Codrituzumab (DB14843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codrituzumab 1600 mg qw + Sorafenib 400 mg bid
Study: 28120158
Drug: Liposomal bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine, single 266 mg dose (cohort 1)
Study: 28120158
Drug: Liposomal bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine, two 266 mg doses (cohorts 2-5)
Study: 28120158
Drug: Liposomal bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine, repeated doses at 24, 48, or 72 hours after first dose
Study: 28122201
Drug: PF-02545920, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-02545920, single oral dose administration, dosage not specified
Study: 28122648
Drug: Microbiota Transfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiota Transfer Therapy (MTT) involving a 2-week antibiotic treatment, bowel cleanse, and extended fecal microbiota transplant (FMT) with a high initial dose followed by daily lower maintenance doses for 7-8 weeks.
Study: 28122648
Drug: Microbiota Transfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiota Transfer Therapy (MTT)
Study: 28123778
Drug: Tocilizumab combination
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab combination therapy
Study: 28123890
Drug: Activated and
Normalized name: hepatitis A inactivated and hepatitis B (recombinant) vaccine per 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated and expanded natural killer (NKAE) cells plus anti-myeloma drugs
Study: 28125608
Drug: Salvia Miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia Miltiorrhiza Depside Salt for Infusion (SMDS)
Study: 28126019
Drug: Tele-EMS physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-EMS physician treatment (intervention group)
Study: 28126019
Drug: Conventional EMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional EMS physician treatment (control group)
Study: 28128878
Drug: Cooling treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling treatments
Study: 28129526
Drug: Androgens added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgens added to maintenance therapy
Study: 28129526
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy without androgens
Study: 28129783
Drug: 6-week Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week Internet-based self-help therapy intervention
Study: 28130212
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg/d and dexamethasone 20 or 40 mg once per week
Study: 28130212
Drug: Pomalidomide 2
Normalized name: pomalidomide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 2 mg/d and dexamethasone 20 or 40 mg once per week
Study: 28131167
Drug: IPX066 (carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 (carbidopa and levodopa extended-release capsules)
Study: 28131394
Drug: Soluble VAR2CSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble VAR2CSA protein vaccine
Study: 28131785
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.
Study: 28131785
Drug: Nivolumab treatment-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment-related adverse events.
Study: 28131785
Drug: Nivolumab treatment-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment-related deaths.
Study: 28132845
Drug: ivacaftor treatment
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ivacaftor treatment (4 weeks)
Study: 28132845
Drug: ivacaftor treatment
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ivacaftor treatment (48 weeks)
Study: 28134742
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine challenge after initial anti-HBs testing
Study: 28135273
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated JE vaccine SA14-14-2
Study: 28135777
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg) + Daclatasvir (60 mg) once daily for 12 weeks
Study: 28135777
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg) + Daclatasvir (60 mg) once daily for 24 weeks
Study: 28135777
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg) + Daclatasvir (60 mg)
Study: 28137593
Drug: Ledipasvir-sofosbuvir for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir-sofosbuvir for 12 weeks (90/400 mg once daily)
Study: 28137593
Drug: Ledipasvir-sofosbuvir for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir-sofosbuvir for 8 weeks (90/400 mg once daily)
Study: 28138028
Drug: Chk1/2 inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chk1/2 inhibition with prexasertib combined with EGFR inhibitor cetuximab and radiotherapy
Study: 28138560
Drug: BTK inhibitor
Normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTK inhibitor ibrutinib
Study: 28139016
Drug: Intra-articular (IA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular (IA) Autologous Protein Solution (APS) 50 μl from a human donor
Study: 28139235
Drug: Probability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probability of pregnancy at 1 year after arrest of medical treatment
Study: 28140719
Drug: Delanzomib (CEP-18770)
Normalized name: Delanzomib
DrugBank: Delanzomib (DB11956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delanzomib (CEP-18770) at maximum tolerated dose (MTD) of 2.1 mg/m², administered on days 1, 8, and 15 in 28-day cycles.
Study: 28143447
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 μg once-daily for 5 months
Study: 28144789
Drug: AZD5363 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5363 combined with docetaxel and prednisolone chemotherapy (DP)
Study: 28144789
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and prednisolone chemotherapy (DP)
Study: 28146642
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo or standard treatment)
Study: 28148221
Drug: Seasonal adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal adjuvanted influenza vaccine (Fluad™, Novartis) with five follow-up visits (day 0, 1/3, 7, 21, 70)
Study: 28148281
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) usage
Study: 28148281
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor (TNF) blockers usage
Study: 28148635
Drug: High-dose immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation (HDIT/HCT)
Study: 28150872
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan followed by HSCT
Study: 28151941
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (training and support in intensive multifactorial treatment)
Study: 28151941
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (intensive treatment and routine care)
Study: 28152086
Drug: NKTT120 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTT120 (0.1 mg/kg, 0.3 mg/kg, 1 mg/kg)
Study: 28152086
Drug: NKTT120 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTT120 (0.3 mg/kg, 1 mg/kg)
Study: 28152975
Drug: Cuff inflation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuff inflation to recommended volume (#3: 60 ml, #4: 80 ml, #5: 90 ml)
Study: 28155045
Drug: Alisertib (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (selective aurora kinase A inhibitor)
Study: 28155203
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted psychoeducation (CaPE) plus Treatment As Usual (TAU)
Study: 28157063
Drug: Cumulative amounts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative amounts of harmful excipients (ethanol, propylene glycol, benzyl alcohol, parabens, acesulfame p, aspartame, glycerol, sorbitol, polysorbate-80) administered during hospitalization.
Study: 28157173
Drug: Nickel patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel patch test in NCWS patients
Study: 28158311
Drug: BI-505, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, administered as 5 doses totaling 43 mg/kg BW over a 7-week period.
Study: 28158395
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge with S. Paratyphi A at a dose of 1-5 × 10^3 CFU
Study: 28158395
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge with S. Paratyphi A at a dose of 0.5-1 × 10^3 CFU
Study: 28158395
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment started when prespecified diagnostic criteria were met or at day 14 postchallenge
Study: 28158463
Drug: Ramucirumab 6
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 6 mg/kg Q2W (N = 3)
Study: 28158463
Drug: Ramucirumab 8
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 mg/kg Q2W (N = 6)
Study: 28158463
Drug: Ramucirumab 10
Normalized name: ramucirumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab 10 mg/kg Q3W (N = 6)
Study: 28158504
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) including tenofovir disoproxil fumarate
Study: 28158551
Drug: Concurrent reactivations
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent reactivations of herpesviruses (CMV, EBV, HHV-6, HSV-1, HSV-2, VZV)
Study: 28158551
Drug: Concurrent CMV
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent CMV and EBV reactivations
Study: 28159192
Drug: rFIXFc prophylaxis
Normalized name: rFIXFc
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFIXFc prophylaxis (50-60 IU/kg) once per week, adjusted to ≤100 IU/kg per infusion or up to two times per week as needed
Study: 28159512
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (CCB) therapy
Study: 28159590
Drug: Polygenic risk
Normalized name: polygalic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polygenic risk scores (PRS) for antidepressant efficacy
Study: 28159590
Drug: Stratified by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified by antidepressant (escitalopram or citalopram)
Study: 28159728
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of flaxseed lignan (secoisolariciresinol diglucoside; SDG) daily
Study: 28159938
Drug: Sulfatinib formulation
Normalized name: SULFATINIB
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfatinib formulation 2 (50 and 200 mg capsules)
Study: 28159938
Drug: Sulfatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfatinib (300 mg recommended phase II dose)
Study: 28161120
Drug: Venetoclax (ramp-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (ramp-up treatment 20-200 mg) with posaconazole (20 mg)
Study: 28161120
Drug: Venetoclax (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (reduced dose)
Study: 28161570
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine (Shanchol)
Study: 28161570
Drug: No exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exposure to oral cholera vaccine
Study: 28162825
Drug: Quadrivalent live
Normalized name: influenza vaccine quadrivalent live 2015-2016 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent live attenuated influenza vaccine (Q/LAIV)
Study: 28162825
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (IIV) recipients
Study: 28163748
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment with weight loss